PURCHASE OPTIONS

Contact one of our authorized distributors listed below to order DEXTENZA and receive it by the next business day.

Distributor Info
Phone
Fax
Website
Besse Medical
1-800-543-2111
1-800-543-8695
Cardinal Specialty
Pharma Distribution
1-855-855-0708
1-614-553-6301
FFF Enterprises
1-800-843-7477
1-800-418-4333
Henry Schein Medical
1-800-772-4346
1-800-329-9109
Metro Medical
1-800-768-2002
1-615-256-4194
McKesson
Medical-Surgical
1-855-571-2100
1-800-311-3408
McKesson Plasma &
Biologics for Hospitals
1-877-625-2566
1-888-752-7626
McKesson
Specialty Health
1-855-477-9800
1-800-800-5673

Ocular Therapeutix does not recommend the use of any particular distributor.

Product
Active Ingredient
Size
NDC #
DEXTENZA
(dexamethasone ophthalmic insert) 0.4 mg
(dexamethasone USP)
1's
70382-0204-01
DEXTENZA
(dexamethasone ophthalmic insert) 0.4 mg
(dexamethasone USP)
10's
70382-0204-10

For further purchase inquiries, please contact your distributor or Ocular Therapeutix

Customer Service: 1-888-315-7906
Monday – Friday 9 AM – 3 PM ET

Billing and Coding

Codes needed to ensure proper billing for DEXTENZA

J-code: J1096

Additional codes needed to ensure proper billing for DEXTENZA

J-code

J1096

DEXTENZA
CPT Code®

0356T

DEXTENZA Administration
CPT Modifiers

RT/LT

Right Eye/Left Eye
NDC Number*

70382-0204-01,
70382-0204-10

1-insert carton,
10-insert carton

How is a pass-through product coded and billed?

  • A unique J-code (J1096) allows ASCs and HOPDs to bill Medicare and other payers for DEXTENZA
  • The payment is in addition to facility fees paid to ASCs or HOPDs for cataract surgery

No effect on physician fees

  • Payment to surgeons for cataract surgery under Medicare’s Physician Fee Schedule will not be affected by the pass-through payment status of DEXTENZA

No effect on the healthcare system

  • Pass-through regulation is budget-neutral to the healthcare system
  • If surgeons and/or facilities do not access pass-through payments, the allotted funds will be used by other specialties and any remaining amounts will be lost

DEXTENZA360™ provides comprehensive support for obtaining benefits verification and determining the appropriate codes preferred by the payer.

Coverage and reimbursement may vary by payer, contractual agreements, and site of service.

Work with your DEXTENZA Field Reimbursement Manager to determine billable status for your payers and identify which plans allow for separate payment of drugs, new technologies, and pass-through drugs.

*For billing, certain payers may require the 10-digit NDC to be converted to 11 digits.

CPT copyright 2019 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

ASC = ambulatory surgical center; CMS = Centers for Medicare and Medicaid Services; CPT = Current Procedural Terminology;

  open
  close
Full Prescribing Information
INDICATION

DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

IMPORTANT SAFETY INFORMATION

Contraindications
DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

Warnings and Precautions
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Adverse Reactions
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

Please see Full Prescribing Information.